Nexalin Technology, Inc.

Equities

NXL

US65345B2016

Advanced Medical Equipment & Technology

Delayed Nasdaq Other stock markets 11:51:26 2024-05-01 am EDT			5-day change	1st Jan Change
1.5 ^USD	-1.96%		+5.63%	+270.55%

Apr. 25	Nexalin Technology Regains Compliance With Nasdaq Listing Requirement	MT
Apr. 16	Nexalin Technology Files $5.6 Million Shelf Registration	MT

Nexalin Technology : unveils positive results of clinical study for Gen-2 tACS device

April 18, 2024 at 12:13 pm EDT

Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device

Investor Relations, Videos

April 18, 2024 12:07 PM

Link to siteHERE.

Attachments

Original Link
Permalink

Disclaimer

Nexalin Technology Inc. published this content on 18 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 April 2024 16:12:06 UTC.

Latest news about Nexalin Technology, Inc.

Nexalin Technology Regains Compliance With Nasdaq Listing Requirement	Apr. 25	MT
Nexalin Technology Files $5.6 Million Shelf Registration	Apr. 16	MT
Nexalin Technology Accelerates Manufacturing of Its HALO? Clarity Following Successful Usability, Feasibility, and Electrical Testing	Apr. 09	CI
Nexalin Technology, Inc. Announces the Appointment of William A. Hudson, Jr. to Military & Government Advisory Board	Apr. 02	CI
Top Midday Gainers	Mar. 28	MT
Nexalin Technology, Inc. Announces Positive Results of Clinical Study Validating its Gen-2 TACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego	Mar. 28	CI
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Nexalin Technology, Inc. Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman	Mar. 14	CI
Nexalin Technology, Inc. Announces Positive Results from Clinical Study of Its Gen-2 Tacs Device for Treating Adult Patients with Chronic Insomnia	Mar. 06	CI
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device	Feb. 08	CI
Nexalin Technology, Inc. Unveils Gen-3 HALO?? Clarity 15 Milliamp Neurostimulation Device	Jan. 11	CI
Nexalin Technology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Nexalin Technology, Inc. Announces Publication of Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal	23-10-16	CI
Nexalin Technology, Inc. Announces Resignation of Marilyn Elson as Chief Financial Officer	23-09-28	CI
Nexalin Technology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of Its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms	23-08-07	CI
Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin's TACS Devices in the Asia Pacific Region	23-06-01	CI
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27	CI
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27	CI
Certain Warrants of Nexalin Technology, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2023.	23-03-15	CI
Certain Common Stock of Nexalin Technology, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2023.	23-03-15	CI
Nexalin Technology, Inc. Appoints Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory	23-01-24	CI
Top Premarket Gainers	22-12-27	MT
Nexalin Technology, Inc.(NasdaqCM:NXL) added to S&P TMI Index	22-12-19	CI

Chart Nexalin Technology, Inc.

Duration

Period

More charts

Company Profile

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Sector

Advanced Medical Equipment & Technology

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
NEXALIN TECHNOLOGY, INC.	+270.55%	11.38M
THERMO FISHER SCIENTIFIC	+7.97%	217B
DANAHER CORPORATION	+6.24%	183B
INTUITIVE SURGICAL, INC.	+10.54%	131B
BOSTON SCIENTIFIC CORPORATION	+24.74%	106B
SIEMENS HEALTHINEERS AG	-0.95%	62.16B
EDWARDS LIFESCIENCES CORPORATION	+10.61%	51.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.81%	50.89B
AGILENT TECHNOLOGIES, INC.	-0.63%	40.16B
GE HEALTHCARE TECHNOLOGIES INC.	+1.40%	34.79B

Other Advanced Medical Equipment & Technology